SQLite Web: event_store.db

Update row sig_9ec35fa953d7 in signals

id

Primary key. TEXT

event_id

TEXT NOT NULL

watcher_id

TEXT

signal_type

TEXT NOT NULL

value

{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000007.txt","as_of":"2026-04-08T02:28:02.401723+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000007.txt","company":"UNITED THERAPEUTICS Corp","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000007.txt","article_chars":5000,"article_truncated":true,"blocked_reason":null,"candidate_id":"sc_58fd78b60a988162","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000007.txt","content_type":"text/plain","enriched_at":"2026-04-08T03:36:15.221430+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000007.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000007.txt","source_event_id":"evt_c77124be7975","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"20dfb2f20b8293ea","kind":"sec_filing","published_at":"20260407","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.78,"dates_mentioned":["2026-04-07","2026-04-06","2025-10-31","2023-03-15","2027-03-15"],"entities":[{"asset_class":"equity","name":"UNITED THERAPEUTICS Corp","relevance":"high","symbol":"UTHR","type":"issuer"},{"asset_class":"person","name":"EDGEMOND JAMES","relevance":"high","symbol":"","type":"reporting_person"},{"asset_class":"person","name":"James Edgemond","relevance":"high","symbol":"","type":"reporting_person_alias"}],"event_type":"other","information_gaps":["The signal indicates a 'delta' vs prior known state, but no prior filing/state is provided here, so 'what changed' cannot be determined from the supplied text alone.","The cleaned text is truncated at the end ('The reporting person h'), so the full set of transactions/quantities and any concluding statements may be missing.","While multiple price ranges are provided, the total number of shares bought/sold and the net effect are not explicitly summarized in the provided excerpt.","The filing shows multiple line items with quantities and prices, but the excerpt does not clearly label which lines correspond to exercise vs sale beyond the presence of 'Stock Option' and 'Common Stock' entries."],"key_facts":["SEC filing: Form 4 (CONFORMED SUBMISSION TYPE: 4) for United Therapeutics Corp (issuer).","Filed as of date: 2026-04-07; conform ed period of report: 2026-04-06.","Reporting owner: EDGEMOND JAMES; role shown as CFO AND TREASURER.","Security types shown include Common Stock and Stock Option.","The filing states the transaction was executed pursuant to a Rule 10b5-1 trading plan entered into on October 31, 2025.","The filing states the transaction was executed in multiple trades at prices ranging from $561.12 to $562.02 (weighted average price reflected above).","The filing includes additional repeated statements of multiple trades with other price ranges (e.g., $562.20 to $563.16; $563.20 to $563.96; $564.23 to $564.635; $565.99 to $566.04; $552.38 to $553.00; $553.61 to $554.55), each noting weighted average price and an undertaking to provide full information upon request."],"numeric_claims":[{"label":"Form filed as of date","value":"2026-04-07"},{"label":"Conformed period of report","value":"2026-04-06"},{"label":"Rule 10b5-1 plan entry date","value":"2025-10-31"},{"label":"Option exercise price shown (example line)","value":"135.42"},{"label":"Common stock sale price range (one stated range)","value":"$561.12 to $562.02"},{"label":"Common stock sale price range (another stated range)","value":"$552.38 to $553.00"}],"primary_claim":"On 2026-04-06, United Therapeutics reported (Form 4) that CFO/Treasurer James Edgemond exercised stock options and sold shares of UTHR common stock under a Rule 10b5-1 trading plan dated 2025-10-31.","relevance_score":0.55,"sentiment":"neutral","source_quality":"high","summary":"United Therapeutics (UTHR) filed Form 4 on 2026-04-07 covering transactions by reporting person James Edgemond (CFO and Treasurer) related to stock option exercises and subsequent sales of common stock. The filing states the trades were executed under a Rule 10b5-1 trading plan entered on 2025-10-31.","topics":["SEC Form 4","insider trading","stock option exercise","Rule 10b5-1 trading plan","common stock sales"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 UNITED THERAPEUTICS Corp \u00b7 Filed 20260407","ticker":"UTHR","tickers":["UTHR"],"title":"UTHR filed 4","url":"https://www.sec.gov/Archives/edgar/data/1082554/0001636178-26-000007.txt"}

TEXT NOT NULL

threshold

TEXT

direction

TEXT

severity

TEXT

window

TEXT

source

TEXT NOT NULL

reason_trace

TEXT

dedupe_key

TEXT NOT NULL

throttle_s

INTEGER (default 0

created_at

TEXT NOT NULL (default strftime('%Y-%m-%dT%H:%M:%fZ','now')

Cancel